News All News

Scaling biomanufacturing is often constrained by how efficiently gases move through liquids—FluxBio, a Harvard startup out of the lab of Jarad Mason in the Department of Chemistry & Chemical Biology at Harvard, found a solution by re-engineering the liquid, not the machine. The microporous water technology received critical early support from the Blavatnik Biomedical Accelerator to advance while in the lab and ultimately form the basis for FluxBio.

Connie Cepko reflects on four decades of advancing efforts to prevent or treat vision-threatening disease. The Cepko Lab is highly translational, advancing research with support from the Blavatnik Biomedical Accelerator and by collaborating with industry, resulting in over 40 inventions from the lab.

In a recent Guppy Tank event, Professor Jeffrey Smith received feedback from a panel of investors on a new molecule that could help most sun-sensitive patients, research supported by the Blavatnik Biomedical Accelerator. Harvard's Office of Technology Development and LabCentral co-host the Guppy Tank series, where innovators pitch their early-stage concepts to a panel of entrepreneurs and investors for constructive, in-depth feedback.

For more than three decades, Greg Verdine has brought bold, innovative methods to solving some of medicine’s biggest challenges - from early-stage work backed by the Harvard Blavatnik Biomedical Accelerator to the launch of multiple startups.